Evidence map›Paper›PMID 23568001›Full record

ArticleThe oncologist2013

Long-term risk perceptions of women with ductal carcinoma in situ.

Kathryn J Ruddy, Meghan E Meyer, Anita Giobbie-Hurder, Karen M Emmons, Jane C Weeks, Eric P Winer, Ann H Partridge

Open access · bronzeAbstract read
In one paragraph

Article in The oncologist, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Quality of life issues in patients with ductal carcinoma in situ: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Psychological morbidity in women diagnosed with ductal carcinoma in situ compared with women with early breast cancer receiving radiotherapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020
    Article
  14. Quality of DCIS information on the internet: a content analysis.Breast cancer research and treatment · 2019
    Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. What Factors Influence Women's Perceptions of their Systemic Recurrence Risk after Breast Cancer Treatment?Medical decision making : an international journal of the Society for Medical Decision Making · 2018
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Kathryn J RuddyMedical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA. kruddy@partners.org
Meghan E Meyer
Anita Giobbie-Hurder
Karen M Emmons
Jane C Weeks
Eric P Winer
Ann H Partridge
Dana-Farber Cancer Institute · USHarvard University · US

Funding

Variation in Receptor Tyrosine Kinases and Breast Cancer RiskP50CA089393 · NCI · DANA-FARBER CANCER INSTITUTE · PI HARRIS, LYNDSAY NORINE · 2000 to 2009
$28.8M
NCI NIH HHS 5P50CA89393-03NCI NIH HHS P50 CA089393
6 · The paper itself

Abstract

introductionPrevious research has demonstrated that many women with ductal carcinoma in situ (DCIS) overestimate their risk for future breast cancer at the time of diagnosis and soon thereafter. This study aims to evaluate risk perceptions after 5 years. PATIENTS AND

methodsIn a longitudinal cohort study, we mailed long-term follow-up surveys to 315 women who had previously responded to a survey 18 months after they were diagnosed with DCIS, excluding those who had experienced recurrence and those not treated at our institution. We evaluated risk perceptions with items used previously in the cohort.

resultsOne hundred ninety-three women (61%) responded. The median time since diagnosis was 5.9 years. We excluded 12 because of recurrence. Of the 181 remaining, 32% perceived at least a moderate 5-year risk for developing DCIS again, 43% perceived at least a moderate lifetime risk for developing DCIS again, 27% perceived at least a moderate 5-year risk for invasive breast cancer, 38% perceived at least a moderate lifetime risk for invasive breast cancer, and 24% perceived at least a moderate risk for DCIS spreading to other body parts. In a multivariate model, worse financial status and higher perceived risk in the previous survey were the only predictors of at least a moderate perception of risk for DCIS spreading.

conclusionWomen with a history of DCIS continue to harbor inaccurate perceptions of their risk for future breast cancer events even 5 years after diagnosis.

Indexed as

Risk AssessmentBreast NeoplasmsCarcinoma, Intraductal, NoninfiltratingData CollectionFemaleFollow-Up StudiesHumansNeoplasm Recurrence, LocalPerception

Identifiers

PMID23568001
PMCPMC3639521
OpenAlexW2115854814

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.